RO6889678

CAS No. 1578153-27-1

RO6889678( RO 6889678 )

Catalog No. M12255 CAS No. 1578153-27-1

RO6889678 is a highly potent inhibitor of HBV capsid formation with attributes that are favorable for targeting the liver, whilst maintaining moderate peripheral exposure.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 88 Get Quote
5MG 124 Get Quote
10MG 178 Get Quote
25MG 255 Get Quote
50MG 407 Get Quote
100MG 599 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    RO6889678
  • Note
    Research use only, not for human use.
  • Brief Description
    RO6889678 is a highly potent inhibitor of HBV capsid formation with attributes that are favorable for targeting the liver, whilst maintaining moderate peripheral exposure.
  • Description
    RO6889678 is a highly potent inhibitor of HBV capsid formation with attributes that are favorable for targeting the liver, whilst maintaining moderate peripheral exposure.HBV InfectionPhase 1 Discontinued.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    RO 6889678
  • Pathway
    Microbiology/Virology
  • Target
    HBV
  • Recptor
    HBV
  • Research Area
    Infection
  • Indication
    HBV Infection

Chemical Information

  • CAS Number
    1578153-27-1
  • Formula Weight
    494.922
  • Molecular Formula
    C21H20ClFN4O5S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C([C@H]1N(CC2=C(C(OC)=O)[C@H](C3=CC=C(F)C=C3Cl)N=C(C4=NC=CS4)N2)CCOC1)O
  • Chemical Name
    (S)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kratochwil NA, et al. J Pharmacol Exp Ther. 2018 Feb 16. pii: jpet.117.245712.
molnova catalog
related products
  • ccc_R08

    ccc_R08 is an orally available HBV cccDNA inhibitor that reduces extracellular levels of HBV DNA, HBsAg, and HBeAg in a dose-dependent manner. ccc_R08 is investigational for use in the treatment of HBV infections. ccc_R08 has been shown to be effective in the treatment of hepatitis C virus (HCV).

  • GLP-26

    GLP-26 is a novel potent HBV capsid modulator that reduces secreted HBeAg in HepNTCPDL cells transfected with HBV wild type with EC50 of 0.7 uM.

  • NTCP binder peptide ...

    NTCP binder peptide WD1 is a macrocyclic peptide, pan-genotypic inhibitor of HBV cellular entry via targeting the cell-surface receptor for HBV.